Immune-related Adverse Event
Conditions
Keywords
arthritis, check point inhibitor, irAE
Brief summary
RIMRA is a prospective, longitudinal, observational study including patients with de novo symptoms of rheumatic disease or a flare of established rheumatic disease after treatment with an immune check point inhibitor. The aim of the study is to describe the clinical presentation, disease course and outcome of rheumatic irAEs in patients treated with immune check point inhibitors.
Interventions
OTHERAntiinflammatory/DMARDs
Antiinflammatory/DMARDs
Sponsors
Oslo University Hospital
Alesund Hospital
University Hospital of North Norway
Hospital of Southern Norway Trust
Helse Nord-Trøndelag HF
Diakonhjemmet Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* De novo symptoms of rheumatic disease or a flare of established rheumatic disease after \>/= 1 dose of treatment with an immune check point inhibitor * Adult patients (\> 18 years) * Subject capable of understanding and signing an informed consent form
Exclusion criteria
• Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol difficult
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Swollen joint count | 1 year follow-up | Numbers (0-66) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| C reactive protein | 1 year | mg/L |
| Proportion of pateints with arthritis after one year | 1 year | — |
Countries
Norway
Outcome results
None listed